NeuroPace Inc

NeuroPace insiders, including CFO, CEO, and CMO, are buying RSUs and options at the 52‑week low, signaling confidence amid a positive social‑media buzz and potential upside.

NeuroPace insider buys reveal a bullish shift: COO Morrell’s RSU grant and option purchase suggest confidence in future stock growth, signaling a positive entry point.

NeuroPace insider selling: CMO Martha Morrell sold 1,341 shares at $13.27, reducing holdings to under 50k—what this means for the company’s valuation, pipeline, and investor outlook.

NeuroPace insider buying trend: Lacob Joseph’s recent low‑price purchase signals cautious confidence amid volatile market and declining earnings, hinting at potential upside if clinical milestones boost valuation.

NeuroPace insider sales hint at confidence shifts—Morrell Martha and Joel Becker offload shares amid volatility, guiding investors on future outlook.